Boehringer Ingelheim
For Healthcare Professionals

Document ID: PC-MY-101629

Speaker: Dr. Maximilian Hochmair

Running the Marathon: Updated Evidence on Sequential EGFR TKI Approach in NSCLC (Q&A session)

In the Q&A session facilitated by Dr Cheah Soon Keat, Dr Maximillian Hochmair brought us through the important topics such as determining which patients are suitable for EGFR-TKI sequencing, T790M cut-off value for switching to osimertinib from afatinib and current clinical strategies on patient with L858R mutation.

Expert Conversations

Malaysia Region Tumour Heterogeneity in Lung Cancer Asian setting
MYEEE||EGFR TKI-related Dermatological Adverse Events
MYEEE||Evidence for Sequential Therapy in EGFR M+ NSCLC
MYEEE||Effectiveness of Dose Modification Strategies with Afatinib
MYEEE||Strategies in Managing EGFRM+ NSCLC
Malaysia Region Treatment stratergy with EGFR-TKIs Asian setting
Running the Marathon: Updated Evidence on Sequential EGFR TKI Approach in NSCLC (Q&A session)
Running the Marathon: Updated Evidence on Sequential EGFR TKI Approach in NSCLC (Presentation)
MYEEE||PeRsonalized apprOach in Lung adenocarciNoma with EGFR-TKI therapy (PROLONG)
Uncovering the Uncommon: Efficacy of Afatinib in Uncommon and Compound Mutations
Taking Cancer On Webinar – Let’s TOAST to Maximising Time on EGFR-TKI Therapy (Lecture)
Taking Cancer On Webinar – Let’s TOAST to Maximising Time on EGFR-TKI Therapy (Q&A)

Speaker

qa-dr-maximilian-hochmair-wildbild.jpg

Dr. Maximilian Hochmair

Head of Respiratory Oncology Unit Department of Respiratory & Critical care Medicine, Klinik Floridsdorf Krankenhaus Nord, Brunnerstrabe 68 1210 Vienna/Austria

RELATED CONTENT